Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Anju Ghangurde
Biohaven restructures its migraine partnership with Bristol to reduce its downstream royalty commitments. Meanwhile, the pharma partners with GRYT Health's cancer app for patient/caregiver insights into cancer therapy.
Private equity group ChrysCapital is investing $20m in the Indian firm Curatio Healthcare, underscoring the continuing interest in the niche dermatology space that generally sees healthy margins.
Dr Philip Larsen, Vice President, Research and Translational Medicine, R&D Diabetes Division, Sanofi tells Scrip in an interview which way potential gene therapy for diabetes may be headed and how the Sanofi-Evotec alliance is shaping. He also indicates that oral insulin, considered the holy grail of diabetes treatment, is a ‘really long journey’ with difficult prospects currently.
Shreeram Aradhye, Novartis’s Global Head, Medical Affairs, and Chief Medical Officer (Pharmaceuticals), outlines the company’s all-encompassing-approach for multiple sclerosis therapies. In a wide-ranging interview with Scrip, Aradhye also touches on the promise of gene therapy and how emerging technologies are helping shape medical innovation.